PATENT CLAIM ANALYSIS

Application Number: 16416731
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "278000"]

Abstract:
Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

Claim (Index 34):
The method of  claim 30  that provides an increase in the metastasis-free survival of the male human with prostate cancer, relative to the mean survival rate of a population of male humans, with prostate cancer, said population having been treated with a placebo.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 100.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15851444', '14151106', '16384002', '15975449', '14406520']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8186597982863847
- 35 USC 102 Novelty (BERT): 0.6037402315712348
- Combined Prediction Score: 0.7971678416148698
- Mean Citation Score: 538.8045
- Max Citation Score: 736.50757
- Similarity Product: 425.9371212237817

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test